BIOCHEMICAL AND GENTIC STUDY OF EGYPTIAN PATIENTS WITH MUCOPOLYSACCHARIDOSIS

Thesis

Submitted For Partial Fulfillment of The M.D Degree In Medical Human Genetics

By

Nermine M. Bahaa El- Din Ahmed M.Sc. of Medical Human Genetics Faculty of Medicine, Ain Shams U

Under the supervision of
Prof.Dr.Rabah Mohammed Shawky
Professor of Pediatrics & Genetics
Faculty of Medicine, Ain-Shams University

Prof.Dr.Eman Ahmed Zaky Professor of Pediatrics Faculty of Medicine, Ain-Shams University

Prof.Dr.Ekram Maher Fateen Professor of Biochemical Genetics National Research Center

Prof.Dr. Mahmoud Refaat Professor of Genetics Suez Canal University

Contents

		page
-	Introuduction	١
-	Aim of the work	٤
-	Review of the literature Chapter I	
	Lysosomal Storage Disorders	٥
	Mucopolysaccharidoses	
	Historical overview Enzymes of Glycominoglycans Degrdation Enzyme deficiency in the various types of M Clinical Manifestations of MPS Chapter II	17 19 PS 71 70
	Prevention of MPS Carrier detection Prenatal diagnosis of MPS Radiological Manifestation of MPS Biochemical Diagnosis of MPS Molecular Study of MPS Chapter III	7. 71 70 70
	Treatment of MPS Management of Complications of MPS	9 Y 1 Y £
_	Subjects and Methods	١٣٠

-	Results	150
_	Discussion	179
-	Conclusions	197
_	Summary	198
-	Recommondations	197
-	References	191

- Arabic summary

List of Figures

Figure	Title	Page
١	Transport of a Lysosomal Enzyme in a Normal Cell	٧
۲	Autosomal inheritance	٩
٣	patients with Hunter syndrome	١٣
٤	Professor Luis Morquio	١٤
٥	Morquio syndrome	10
٦	Step wise degradation of dermatan sulfate	71
٧	Step wise degradation of kertan sulfate	7 £
٨	Step wise degradation of Heparan sulfate	70
٩	Step wise degradation of chondroition sulfate and hyaluronan.	**
١.	Patient with Hurler syndrome.	٣٧
11	Bilateral papilledema.	٣٩
١٢	Corneal clouding.	٤٠

١٣	A patient with Scheie syndrome.	٤٠
١٤	pebbly ivory colored skin lesion.	٤٣
10	A patient with Hunter syndrome.	٤٦
١٦	A patient with Sanifilippo syndrome.	٤٨
١٧	A patient with Morquio syndrome.	01
١٨	A patient with Matreaux Lamy syndrome.	٥٣
19	A child with Sly syndrome.	٦٦
۲.	Prenatal diagnostic testing	٦٦
*1	Radiological findings of MPS showing dysostosis multiplex	٧٤,
77	Pie chart shows sex distribution among studied patients with different types of MPS.	150
77	Pie chart shows frequency distribution of consanguinity among studied patients with different types of MPS.	١٤٧

Yź	Pie chart shows frequency distribution of family history among studied patients with different types of MPS.	١٤٨
70	Bar graph shows the clinical manifestations among patients with different types of MPS	10.
Y 7	Bar graph shows skeletal abnormalities among studied patients with different MPS subtypes.	101
77	GAGs value for MPS	107
7.1	GAGs value for MPS II	105
۲۹	GAGs value for MPS III	108
٣.	GAGs value for MPS IV	105
٣١	GAGs value for MPS VI	100
٣٢	a:Normal GAGs Pattern	107
	b: Big Dermatan Sulphate Pattern	107
	c:Dermatan &Heparan Sulphate Pattern	104
	d: Heparan Sulphate Pattern	104

٣٣	a :Normal amniotic fluid	101
	b: Amniotic fluid of fetus affected with type II	101
	c :Amniotic fluid of fetus affected type III	109
٣٤	The clinical features of patient no (1) with MPS IH.	17.
70	plain x-ray of the vertebral columen of the patient no (1) showing beaking of lumbar vertebrae.	١٦١
٣٦	Family pedigree of patient no (1) with MPS IH.	١٦١
٣٧	The clinical features of patient no (\(^{\forall}\)) with MPS II.	١٦٢
٣٨	Plain x-ray of the chest of the patient no	
	(V) showing spatulated ribs.	١٦٢
٣٩	Family pedigree of patient no (\(^{\forall}\)) with MPS II.	174
٤٠	the clinical features of patient no (') with MPS III.	١٦٣
٤١	x-ray of the skull of the patient no ()) showing thickness of the clavaria.	175
٤٢	Family pedigree of patient no ('') with	١٦٤

	MPS III.	
٤٣	the clinical features of patients no (17) with MPS IV.	170
£ £	Plain x-ray of the vertebral columen of the patient no (17) showing oval shaped lumbar vertebrae	170
٤٥	Family pedigree of patient no (١٦) with MPS IV.	177
٤٦	The clinical features of patients no (19) with MPS IV.	177
٤٧	Plain x-ray of the chest of the patient no (19) showing spatulated ribs.	177
٤٤	Family pedigree of patient no (19) with MPS IV.	١٦٨

List of Tables

Table	Title	Page
١	Classifications lysosomal disorders	11
۲	Classifications of types of MPS	٥٩
٣	Sex distribution among studied patient with different types of MPS.	150
٤	Distribution of chronological age and age of onset of clinical of studied patients with different types of MPS.	
٥	Frequency distribution of positive consanguinity and family history among studied cases of MPS	
٦	Clinical manifestations among studied patients with different types of MPS	
٧	IQ distribution among studied patients with different MPS subtypes	
٨	Sketetal abnormalities among studied patients with different MPS subtypes	101
9	The detected GAGs value, resutls of -DEP, and enzymatic assay of studied with different MPS subtypes	107

١.		100
	7-DEP results of amniotic fluid of four mothers	
	of studied index cases with MPS.	

Acknowledgement

First and foremost, I always feel indebted to "ALLAH" the most beneficent and merciful.

Words cannot express the depth of my gratitude to my eminent professor, Prof. Dr. Rabah Mohammed Shawky, Professor of Pediatrics and Genetics, Faculty of Medicine, Ain Shams University, for her valuable suggestions, generous assistance, kind support, continuous and patient encouragement throughout this work. It is a great honour to work under her supervision.

My great appreciation and profound thanks to **Prof. Dr. Eman Ahmed Zaky**, Professor of Pediatrics, Faculty of Medicine, Ain Shams University, for her unlimited help, kind support, valuable supervision, remarkable guidance and fruitful advice.

I would like to express my deepest gratitude and profound thanks to **Prof. Dr. Ekram Maher Fateen**, Professor of Biochemical Genetics, National Research Center for her precious time, active participation, great help and honest assistance to complete this work.

I would like to express my deepest gratitude and profound thanks to **Prof. Dr. Mahmoud Refaat**, Professor of Genetics, Sues Canal University for his kind help and support. Also, I would like to express my appreciation to my colleagues in the Genetics Center, Ain Shams University for their help .Thanks to them, all.

Introduction

The mucopolysaccharidosis (MPS) are a group of heritable disorders each of which is produced by a deficiency of an enzyme required for the lysosomal degradation of sulfated glycosaminoglycans (*Neufeld and Meenzer*, * . . 1).

Mucopolysaccharides (or glycosaminoglycans) are large macromolecules composed of repeating frequently sulfated, disaccharide units attached to a protein core. A series of lysosomal acid hydrolases degrades the glycosaminoglycans by step-wise removal of the sulfates and carbohydrate residues (*Neufeld and Meenzer*, Y···).

There are ' known enzyme deficiency that give rise to six distinct MPS. Most of these enzymes have been extensively purified, their biosynthesis and processing have been elucidated and their primary structure determined from the sequence of the corresponding cDNAs (*Meenzer*, *..**).

Clinical symptoms eventually result from the lysosomal storage of the partially degraded glycosaminoglycans (*Scott et al.*, 1990).

Incompletely degraded glycosaminoglycans accumulate in multiple organ systems leading to progressive worsening of the clinical manifestation. MPS share many clinical features, though in variable degrees. These include a chronic and progressive course, multisystem involvement, organomegaly, dystosis multiplex and abnormal facts. There is clinical similarity between different enzyme deficiencies and conversely a wide spectrum of clinical severity within any one enzyme deficiency (*Muenzer*, Y., Y).

The MPS are inherited as autosomal recessive traits with the exception of the two subtypes of Hunter's disease, which are X-linked recessive (*Muenzer and Fisher* Y··Y).

Disorders that result in heparan sulfate storage have progressive central nervous system involvement. Affected patients may have macrocephaly and develop communicating hydrocephalus. Dermatan sulfate storage is associated with progressive visceral and bone involvement. Affected patients may have hepatosplenomegaly, cardiomyopathy or cardiac valvular involvement (*Muenzer*, Y...Y).

The cardiac and ocular manifestation are common in Egyptian patients with MPS. So regular cardiac examination, echocardiography and eye examination with slit lamp, fundus examination and regular measurement of the intraocular pressure in patients with MPS is necessary (*Shawky et al.*, $? \cdot \cdot ?$).

Hurler syndrome or mucopolysaccharidosis type ' (MPS-') was one of the first to be described (*Hurler*, '۹'۹). It result from deficient activity of a-L-iduoronidase (*Scott et al.*, '۹۹°).

Simple enzyme assays are available for the diagnosis the MPS, prenatal diagnosis following amniocentesis or chorionic villus biopsy is possible for all MPS. (Wenger et al.,).

Scott et al., ($\$ ^ $\$ ^ $\$) demonstrated that the IDUA gene spans approximately $\$ ^ $\$ Kb and it split into $\$ ^ $\$ exons. The first $\$ ^ $\$ exons are separated by an intron of $\$ ^ $\$ ^ $\$ 0 bp; a large intron of approximately $\$ ^ $\$ Kb follows and the last $\$ ^ $\$ 0 exons are clustered within $\$ ^ $\$ 0 Kb.

Bunge et al., $(\ ^{99})$ found that the $\ ^{7}$ common nonsense mutations, $W^{2} \cdot ^{7}x$ and $Q^{7} \cdot ^{7}x$ were identified in 77 and 70 of mutant alleles respectively. He identified 77 novel and 79 previously reported mutations of IDUA, covering 70 of mutant alleles and 77 of genotypes. In Caucasian population, the mutation trp 27 -to-ter had previously been identified as a common MPSI mutation.

Supportive management with particular attention to respiratory and cardiovascular complications improve the quality of life for patients and their families. Early diagnosis of mucopolysaccharidosis is important because of the effectiveness of bone marrow transplantation and enzyme replacement therapy as efficient methods of treatment of MPSI before the appearance of manifestations (*Muenzer*, *..**).